Countless statistical methods have been described for the analysis of DNA microarrays, and each yields distinct results. This raises the question whether DNA microarrays are robust diagnostic tools.
Introduction
The most promising clinical potential for DNA microarrays lies in sample classification for diagnostic purposes [1] [2] [3] [4] . More accurate diagnosis may allow more precise prognosis, and thus, determine therapeutic decisions.
It has become clear that gene clusters ("signatures"), rather than the expression of individual genes, yield higher information contents. The ultimate aim is to move from signatures to models, that is, to analyze the data, integrate the information, and thus, gain knowledge 1 .
The information contained in the expression data is made available through a sequence of statistical analyses, which are not yet standardized. Most reports on DNA microarray data feature a very unique methodology. This makes comparison of results very difficult 5 .
When assessing the clinical usefulness of a new diagnostic technique, several points must be taken into consideration. One is the consistency or robustness of the clinical interpretation of the technology, i.e. a positive answer to the question whether different observers will come to the same conclusion by using this diagnostic technique.
Another is the diagnostic gain, i.e. a positive answer to the question whether the new technology allows better (faster, more reliable, cheaper) diagnosis than the currently used best standard technology.
The present study formally addresses the first of these questions. More precisely, we ask: if one and the same set of microarray data is analyzed using different statistical tests at the same analytic step, will the final conclusions remain the same?
In addition, we discuss indirect hints on the potential diagnostic gain from the use of DNA microarrays for cancer classification.
Results
The comparison of inter-test agreement for the selection of genes produced low kappa scores: only one of the ten comparisons yielded "substantial" agreement, while three each gave "slight", "fair" and "moderate" agreement (Table 1 ) 6, 7 . If the five gene sets are then used to classify the remaining samples for diagnosis, the inter-test agreement scores are far higher ( Table 2 ). All kappa scores show "substantial" or "almost perfect"
agreement.
In order to compare agreement with the standard clinical diagnosis of each sample
given by Golub 8 , we calculated kappa scores for each statistical method. In this comparison, the tests showed κ -scores from 0.58 to 0.88 (Table 3) . One each would thus be considered to show "moderate" or "substantial" agreement with the clinical diagnosis, while the three others had "almost perfect" agreement" 6, 7 .
Discussion
The stepwise calculation of κ-scores showed low average κ-scores, indicative of only "fair" agreement at the gene selection stage but "substantial" agreement for sample classification, and for agreement with the clinical diagnosis. This apparent discrepancy can be explained by the large "marginal imbalance" between selected genes (n=50) and unselected genes (n=6095) 9, 10 at the selection step, and the good balance at the classification step.
From a purely statistical point of view, the good inter-test agreement is already reassuring. Dudoit, however, pointed out that statistical significance is not the same as biological significance in the interpretation of DNA microarray expression profiles 11 . We
have been able to demonstrate that, using this same data set with the intention to identify biological pathways, the same statistical tests lead to a much less robust knowledge gain 12 .
The observation of diagnostic robustness made here becomes thus much less trivial than the use of formally similar statistical tests might suggest.
When using microarrays for diagnostic purposes, they should be expected to agree as much or better than experienced clinicians would agree on the diagnosis.
From a clinical perspective, the diagnostic agreement with κ -scores from 0.58 to 0.88 (Table 3 ) is very competitive. McCarthy's recent study of 462 cases of leukemia showed kappa scores between 0.58 and 0.94 using histomorphology as diagnostic criterion 13 . Of the 26 inter-tester comparisons reported in that study, 12 achieved a kappa score of 0.8 or above, which is commonly regarded as "almost perfect" inter-tester agreement 6, 7 .
The results presented here support the hope 14 that microarrays with large gene sets may yield knowledge from small sample numbers and thus facilitate clinical diagnosis.
Previous studies observed that the same data set, depending on which statistical method the researcher chooses to make use of, may provide considerably different "knowledge" gain. Suarez-Farinas' re-analysis of raw data from three different microarray experiments on the same tissue, now using the same statistical methods throughout, resulted in much more coherent conclusions than the previous comparison of the reported results had obtained 5 . In other words, a standardized approach to analyzing distinct raw data sets makes comparisons across technical platforms possible, while reanalysis of the same distinct data sets with different approaches increases the confusion rather than the knowledge gain. Using a standardized approach to handling the raw data derived from DNA expression microarrays has thus emerged as a key issue in the biological interpretation of the statistical findings, whether at the individual study level or for meta-analysis of such studies 15 .
As the kappa scores reported here are from a different data set than those Technical problems concerning the reproducibility of findings even on the same platform have sparked research that resulted in more reliable data acquisition and analysis methods. By today, much information is gained from studies that use cross-platform approaches and have advanced from the lab bench close to the bedside 7, 17, 18 . In particular, Suarez-Farinas provided evidence that a normalized approach to data analysis will result in higher coherence of results 5 , while Michiels et al have drawn attention to the need to critically appraise this information before eventually accepting the newly gained knowledge 19 .
The results presented here show that microarray analysis has reached a level of intertest agreement similar to that seen in experienced clinicians. This observation should encourage clinicians to consider using microarray analysis as part of diagnostic procedures.
Methods
We assessed the inter-test agreement as described by Cohen's κ-score between five statistical tests 8, [20] [21] [22] [23] used in the analysis of DNA microarray expression data 24 . The data set analyzed was from the well characterized study on acute leukemia by Golub et al.
which has a detailed methodology section that allows stepwise replication of the analysis 8 .
The authors have updated their methodology and allow download from a dedicated website 25 . Appendix Part A gives a brief explanation of the five tests used, of Cohen's kappa score, and of the original dataset. At the level of gene selection, Golub et al.
employ an algorithm that requires specification of the number of genes one hopes to select from the "training" set of samples. Accordingly, we used alternative statistical approaches [20] [21] [22] [23] with the same formal requirement for comparison. The resulting five sets of selected genes ("signatures") are then used to classify independent "case" samples. 
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